Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Chief Business Officer | July 02, 2024 | July 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date July 02, 2024 · Filed July 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33 |
Reported balance
After 2024-07-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-07-02 · Sale · Disposed 2,467 · Balance 33 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.74 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The shares sold in the reported transactions include an aggregate 2,500 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-07-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-07-02 · Sale · Disposed 33 · Balance 0 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.74 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The shares sold in the reported transactions include an aggregate 2,500 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2021 Filed Jun 3, 2021 21:48 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 575 | $2.19 | $1,259.25 |
DisclosureSEC source: 0001209191-21-037839 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,600 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017874 · doc4.xml · derivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,600 Underlying: Common Stock · 65,600 shares Expires 2031-03-01 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| January 06, 2021 Filed Jan 6, 2021 22:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 32 | $57.14 | $1,828.48 |
DisclosureSEC source: 0001209191-21-002246 · doc4.xml · nonDerivative · entry 6 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-21-002246 · doc4.xml · derivative · entry 7 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,397 Underlying: Common Stock · 5,700 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 200 | $60.51 | $12,101.50 |
DisclosureSEC source: 0001209191-21-002246 · doc4.xml · nonDerivative · entry 5 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.50 to $60.515 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,800 | $59.85 | $107,724.42 |
DisclosureSEC source: 0001209191-21-002246 · doc4.xml · nonDerivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.395 to $60.33 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,200 | $59.02 | $129,836.96 |
DisclosureSEC source: 0001209191-21-002246 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,032 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.395 to $59.355 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,500 | $57.66 | $86,494.05 |
DisclosureSEC source: 0001209191-21-002246 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,232 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.33 to $58.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-21-002246 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 32 shares of Common Stock acquired under the issuer's employee stock purchase plan on December 31, 2020. Read SEC document |
| December 18, 2020 Filed Dec 19, 2020 02:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,015 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-064582 · doc4.xml · derivative · entry 6 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,371 Underlying: Common Stock · 8,015 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/48th of the total shares on February 28, 2018, and then 1/48th of the total shares vest at the end of each month thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 18, 2020 Filed Dec 19, 2020 02:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 8,015 | $60.00 | $480,900.00 |
DisclosureSEC source: 0001209191-20-064582 · doc4.xml · nonDerivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 18, 2020 Filed Dec 19, 2020 02:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 8,015 | $0.60 | $4,809.00 |
DisclosureSEC source: 0001209191-20-064582 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2020 Filed Dec 19, 2020 02:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 41,985 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-064582 · doc4.xml · derivative · entry 5 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,386 Underlying: Common Stock · 41,985 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/48th of the total shares on February 28, 2018, and then 1/48th of the total shares vest at the end of each month thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 17, 2020 Filed Dec 19, 2020 02:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 41,985 | $60.00 | $2,519,100.00 |
DisclosureSEC source: 0001209191-20-064582 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 17, 2020 Filed Dec 19, 2020 02:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 41,985 | $0.60 | $25,191.00 |
DisclosureSEC source: 0001209191-20-064582 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-061591 · doc4.xml · derivative · entry 6 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,097 Underlying: Common Stock · 5,700 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 400 | $52.72 | $21,088.00 |
DisclosureSEC source: 0001209191-20-061591 · doc4.xml · nonDerivative · entry 5 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.63 to $52.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 100 | $51.45 | $5,145.00 |
DisclosureSEC source: 0001209191-20-061591 · doc4.xml · nonDerivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,481 | $50.02 | $124,103.09 |
DisclosureSEC source: 0001209191-20-061591 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.78 to $50.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,719 | $49.19 | $133,743.53 |
DisclosureSEC source: 0001209191-20-061591 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.74 to $49.69 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-20-061591 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2020 Filed Nov 10, 2020 22:42 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 13,414 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-057717 · doc4.xml · derivative · entry 5 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,797 Underlying: Common Stock · 13,414 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 10, 2020 Filed Nov 10, 2020 22:42 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 36,586 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-057717 · doc4.xml · derivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,371 Underlying: Common Stock · 36,586 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/48th of the total shares on February 28, 2018, and then 1/48th of the total shares vest at the end of each month thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 10, 2020 Filed Nov 10, 2020 22:42 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 50,000 | $45.00 | $2,250,000.00 |
DisclosureSEC source: 0001209191-20-057717 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 10, 2020 Filed Nov 10, 2020 22:42 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 13,414 | $2.19 | $29,376.66 |
DisclosureSEC source: 0001209191-20-057717 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2020 Filed Nov 10, 2020 22:42 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 36,586 | $0.60 | $21,951.60 |
DisclosureSEC source: 0001209191-20-057717 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-056950 · doc4.xml · derivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,211 Underlying: Common Stock · 5,700 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,536 | $37.98 | $96,324.89 |
DisclosureSEC source: 0001209191-20-056950 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.41 to $38.32 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,164 | $36.59 | $115,785.00 |
DisclosureSEC source: 0001209191-20-056950 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,536 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.36 to $37.355 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-20-056950 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:12 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-053732 · doc4.xml · derivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,911 Underlying: Common Stock · 5,700 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:12 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,300 | $34.86 | $80,182.60 |
DisclosureSEC source: 0001209191-20-053732 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.635 to $35.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:12 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,400 | $34.33 | $116,717.92 |
DisclosureSEC source: 0001209191-20-053732 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.61 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:12 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-20-053732 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 22:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 17,201 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · derivative · entry 6 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,611 Underlying: Common Stock · 17,201 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 22:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 17,201 | $30.00 | $516,030.00 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · nonDerivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 22:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 17,201 | $2.19 | $37,670.19 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,718 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · derivative · entry 5 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,812 Underlying: Common Stock · 30,718 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 30,718 | $30.00 | $921,540.00 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 30,718 | $2.19 | $67,272.42 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-049551 · doc4.xml · derivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,530 Underlying: Common Stock · 5,700 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 700 | $28.71 | $20,097.63 |
DisclosureSEC source: 0001209191-20-049551 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.53 to $29.06 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,000 | $27.60 | $138,015.00 |
DisclosureSEC source: 0001209191-20-049551 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $27.84 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-20-049551 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 22:04 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,081 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-048841 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,230 Underlying: Common Stock · 2,081 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 22:04 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,081 | $30.00 | $62,430.00 |
DisclosureSEC source: 0001209191-20-048841 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 22:04 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 2,081 | $2.19 | $4,557.39 |
DisclosureSEC source: 0001209191-20-048841 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 20:59 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-044723 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,311 Underlying: Common Stock · 5,700 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 20:59 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,700 | $24.73 | $140,943.33 |
DisclosureSEC source: 0001209191-20-044723 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.35 to $25.03 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 20:59 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-20-044723 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.